Production (Stage)
Ligand Pharmaceuticals Incorporated
LGND
$105.99
$1.811.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 208.90M | 256.17M | 219.64M | 226.93M | 310.59M |
| Total Receivables | 52.93M | 42.45M | 48.73M | 38.68M | 31.04M |
| Inventory | 14.61M | 14.11M | 16.74M | 18.67M | 21.34M |
| Prepaid Expenses | -- | 1.93M | -- | 1.91M | 1.24M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 32.87M | 16.90M | 24.27M | 26.06M | 4.71M |
| Total Current Assets | 309.32M | 331.56M | 309.39M | 312.26M | 368.91M |
|
|
|||||
| Total Current Assets | 309.32M | 331.56M | 309.39M | 312.26M | 368.91M |
| Net Property, Plant & Equipment | 10.49M | 24.81M | 25.19M | 25.46M | 24.38M |
| Long-term Investments | 101.54M | 105.25M | 105.25M | 105.25M | 105.25M |
| Goodwill | 101.54M | 105.25M | 105.25M | 105.25M | 105.25M |
| Total Other Intangibles | 258.39M | 266.65M | 274.91M | 283.16M | 291.42M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 214.79M | 202.60M | 226.98M | 127.10M | 76.94M |
| Total Assets | 905.44M | 941.77M | 954.87M | 866.41M | 913.87M |
|
|
|||||
| Total Accounts Payable | 5.37M | 5.23M | 4.69M | 1.79M | 1.89M |
| Total Accrued Expenses | 21.16M | 25.53M | 13.22M | 9.79M | 7.94M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 883.00K | 1.29M | 1.09M | 1.17M | 1.00M |
| Total Finance Division Other Current Liabilities | 31.27M | 5.06M | 5.77M | 5.81M | 6.99M |
| Total Other Current Liabilities | 31.27M | 5.06M | 5.77M | 5.81M | 6.99M |
| Total Current Liabilities | 58.68M | 37.11M | 24.77M | 18.57M | 17.82M |
|
|
|||||
| Total Current Liabilities | 58.68M | 37.11M | 24.77M | 18.57M | 17.82M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 3.57M | 5.86M | 6.27M | 6.42M | 5.22M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 47.65M | 68.36M | 82.65M | 66.23M | 84.31M |
| Total Liabilities | 109.90M | 111.34M | 113.69M | 91.21M | 107.35M |
|
|
|||||
| Common Stock & APIC | 340.56M | 337.40M | 309.36M | 238.89M | 218.28M |
| Retained Earnings | 456.53M | 498.98M | 530.07M | 537.24M | 589.16M |
| Treasury Stock & Other | -1.56M | -5.94M | 1.75M | -935.00K | -910.00K |
| Total Common Equity | 795.53M | 830.44M | 841.18M | 775.20M | 806.52M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 795.53M | 830.44M | 841.18M | 775.20M | 806.52M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 795.53M | 830.44M | 841.18M | 775.20M | 806.52M |
|
|
|||||